Caitong International Asset Management Co., LTD Corvus Pharmaceuticals, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $102 Billion
- Q4 2024
A detailed history of Caitong International Asset Management Co., LTD transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 20 shares of CRVS stock, worth $97. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20
Previous 20
-0.0%
Holding current value
$97
Previous $107,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CRVS
# of Institutions
96Shares Held
39.9MCall Options Held
1.95MPut Options Held
462K-
Orbimed Advisors LLC San Diego, CA6.94MShares$33.9 Million0.98% of portfolio
-
Samlyn Capital, LLC New York, NY6.67MShares$32.5 Million0.56% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$16 Million18.22% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.03MShares$14.8 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$13.1 Million0.23% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $227M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...